Advaxis rises after FDA lifts clinical hold

Advaxis Inc. (NASDAQ:ADXS) jumped $0.12 (10%) to $1.34 Friday after it said FDA lifted a clinical hold on a Phase I/II combination study that includes the company's axalimogene filolisbac (ADXS11-001).

The trial is evaluating the therapy in combination with PD-L1 inhibitor Imfinzi durvalumab to treat advanced, recurrent or refractory cervical cancer and HPV-associated squamous cell carcinoma of the head and neck (SCCHN). Axalimogene filolisbac is a live Listeria monocytogenes-based immunotherapy expressing E7 transforming protein (human papillomavirus-16; HpV16gp2)...